{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:08Z","timestamp":1790957528376,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Bayer Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.xkme.2023.100730","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:42:49Z","timestamp":1695922969000},"page":"100730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials"],"prefix":"10.1016","volume":"5","author":[{"given":"John M.","family":"Flack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon G.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Jamerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo E.","family":"Farjat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lawatscheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.xkme.2023.100730_bib2","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.xkme.2023.100730_bib3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1681\/ASN.2010090960","article-title":"Racial and ethnic differences in kidney function decline among persons without chronic kidney disease","volume":"22","author":"Peralta","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2023.100730_bib4","unstructured":"United States Department of Health and Human Service. Race, ethnicity, and kidney disease. Accessed 22 September 2022. https:\/\/www.niddk.nih.gov\/health-information\/kidney-disease\/race-ethnicity"},{"issue":"5 suppl 1","key":"10.1016\/j.xkme.2023.100730_bib5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.ajkd.2018.06.021","article-title":"Kidney disease among African Americans: a population perspective","volume":"72","author":"Laster","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.xkme.2023.100730_bib6","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HJH.0000000000002103","article-title":"Prevalence of refractory hypertension in the United States from 1999 to 2014","volume":"37","author":"Buhnerkempe","year":"2019","journal-title":"J\u00a0Hypertens"},{"issue":"3","key":"10.1016\/j.xkme.2023.100730_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfq473","article-title":"Race differences in access to health care and disparities in incident chronic kidney disease in the US","volume":"26","author":"Evans","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2023.100730_bib8","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1053\/j.ajkd.2009.12.032","article-title":"Poverty, race, and CKD in a racially and socioeconomically diverse urban population","volume":"55","author":"Crews","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"24","key":"10.1016\/j.xkme.2023.100730_bib9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.xkme.2023.100730_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2215\/CJN.10761012","article-title":"Differences in progression to ESRD between black and white patients receiving predialysis care in a universal health care system","volume":"8","author":"van den Beukel","year":"2013","journal-title":"Clin J Am\u00a0Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2023.100730_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.xkme.2023.100730_bib12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.xkme.2023.100730_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2023.100730_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"issue":"23","key":"10.1016\/j.xkme.2023.100730_bib15","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.xkme.2023.100730_bib16","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.xkme.2023.100730_bib17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.xkme.2023.100730_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.08980621","article-title":"Potential effects of elimination of the Black race coefficient in eGFR calculations in the CREDENCE trial","volume":"17","author":"Charytan","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"22","key":"10.1016\/j.xkme.2023.100730_bib19","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/sim.8282","article-title":"Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease","volume":"38","author":"Vonesh","year":"2019","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.xkme.2023.100730_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.xkme.2023.100730_bib21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJMp2028243","article-title":"In search of a better equation \u2013 performance and equity in estimates of kidney function","volume":"384","author":"Diao","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.xkme.2023.100730_bib22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.7326\/M20-4951","article-title":"Race and the false precision of glomerular filtration rate estimates","volume":"173","author":"Sehgal","year":"2020","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.xkme.2023.100730_bib23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2023.100730_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-8587(16)30324-2","article-title":"Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes","volume":"5","author":"Hoppe","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.xkme.2023.100730_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/cncr.28483","article-title":"Racial\/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute\u2019s Community Cancer Centers Program","volume":"120","author":"Langford","year":"2014","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.xkme.2023.100730_bib26","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/dom.13805","article-title":"Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? a systematic review and meta-analysis","volume":"21","author":"Mishriky","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.xkme.2023.100730_bib27","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/CIRCULATIONAHA.120.052821","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: racial differences and a potential for reducing disparities","volume":"143","author":"Morris","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.xkme.2023.100730_bib28","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1681\/ASN.2015070763","article-title":"Race, APOL1 risk, and eGFR decline in the general population","volume":"27","author":"Grams","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2023.100730_bib29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tem.2016.02.002","article-title":"Apolipoprotein L1 and kidney disease in African Americans","volume":"27","author":"Friedman","year":"2016","journal-title":"Trends Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.xkme.2023.100730_bib30","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2023.100730_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.kint.2016.09.033","article-title":"Strict blood pressure control associates with decreased mortality risk by APOL1 genotype","volume":"91","author":"Ku","year":"2017","journal-title":"Kidney Int"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059523001486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059523001486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:26:26Z","timestamp":1762910786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059523001486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2590059523001486"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2023.100730","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2023.100730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100730"}}